Biogran

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Biogran

Biogran is the trade name for a prescription-only anti-infective agent containing the active ingredient Cefadroxil. Its purpose is to treat bacterial infections by actively eliminating harmful microorganisms through targeted cellular interference.


Quick Facts: Cefadroxil

Property Description
Active ingredient Cefadroxil
Form Oral Capsule, Tablet, or Suspension
Pharmacological class First-generation cephalosporin antibiotic
Common use Elimination of bacterial pathogens
Origin Semisynthetic

Identity, Classification, and Composition

Cefadroxil is classified as a semisynthetic first-generation cephalosporin antibiotic, which places it within the broader family of beta-lactam antibiotics. This agent provides effective coverage, particularly against susceptible Gram-positive bacteria. The core component is often used in its monohydrate form.

The composition is characterized by acid stability, which is essential because it allows the medicine to be absorbed after being administered orally. The drug requires a prescription (Rx status) and is not available over the counter.

High-Level Purpose and Presentation

Cefadroxil is fundamentally a bactericidal agent, meaning its primary purpose is to kill susceptible bacteria actively rather than just halting their growth. Its mechanism of effect involves the targeted interference with the essential process of bacterial cell wall synthesis. The available oral pharmaceutical preparations include the oral capsule, oral tablet, and a powder for reconstitution as an oral suspension, ensuring that the medicine can be dispensed and taken by a variety of patients, including those who require a liquid formulation.

Regulatory References

  1. Cephalosporins

What side effects are possible with Biogran?

Possible Side Effects and Safety Information

Biogran (Cefadroxil) possesses a safety profile officially documented by regulatory authorities, classifying potential adverse reactions according to frequency and body system. The most frequently documented adverse events are related to Gastrointestinal Disorders and Skin and Subcutaneous Tissue Disorders.


Adverse Reaction Frequencies

Side effects are categorized by their official likelihood of occurrence in regulatory texts:

  • Common (occurring in 1% to 10% of patients) reactions include diarrhea, nausea, vominal, abdominal pain, and rash.
  • Rare (ge 1/10,000 to <1/1,000) reactions include drug fever and angioedema.
  • Very Rare reactions include severe conditions such as anaphylactic shock and Stevens-Johnson syndrome (SJS).

Serious Adverse Reactions and Safety Constraints

The regulatory safety profile highlights several serious and clinically significant reactions. These include the potential for Clostridioides difficile-Associated Diarrhea (CDAD), which can range from mild diarrhea to fatal colitis. Severe allergic reactions such as anaphylaxis and Toxic Epidermal Necrolysis (TEN) have been reported and represent critical documented safety risks.

Safety constraints require particular caution for certain patient groups. The medicine is contraindicated for individuals with a known allergy to the cephalosporin class of antibiotics, noting the risk of cross-sensitivity with penicillins. Additionally, the label advises caution for patients with renal impairment, as unadjusted dosage in this group may be associated with events such as seizures. Prolonged use may result in superinfection due to the overgrowth of non-susceptible organisms, as symptoms of colitis may appear during or after treatment.

Overdose and Emergency Response

Overdose and When to Seek Help

Regulatory information specifies that an overdose of Biogran (Cefadroxil) requires immediate medical intervention. Suspected overdose mandates contacting a Poison Control Center or seeking emergency medical attention without delay. Immediate emergency services must be contacted if the person has collapsed, is experiencing a seizure, has trouble breathing, or cannot be awakened.

Documented Manifestations and Risks

Official documents state that overdose symptoms are primarily dose-dependent and may include gastrointestinal manifestations such as nausea and vomiting. The most severe documented risk is Central Nervous System (CNS) toxicity, which can result in convulsions or seizures. This risk is significantly heightened in patients with impaired renal function due to reduced drug clearance, which leads to high systemic concentrations.

Required Management

The official prescribing information confirms that no specific antidote is known for Cefadroxil overdose. Management is therefore restricted to symptomatic and supportive treatment to address clinical manifestations as they occur. In cases of severe systemic exposure, regulatory documentation notes that hemodialysis is an officially described procedure that can remove substantial amounts of the drug from the bloodstream. Continuous clinical monitoring and hospital observation are typically required following a severe exposure event.

Therapeutic Uses of Biogran

What Biogran Treats: Main Uses and Benefits

Biogran is commonly used to help manage symptoms across specific therapeutic domains, focusing on providing supportive, short-term relief. This class of medication is applied to address mild to moderate discomfort and to reduce fever. This role is considered relevant for:


Symptom Management and Functional Support

Biogran is relevant for conditions characterized by recurrent or episodic manifestations. It assists with maintaining functional stability by managing symptom clusters that fluctuate, such as general body aches, headaches, and temporary fever. It is generally applied during phases of increased distress or discomfort when symptoms become temporarily overwhelming.

“This supportive role helps patients cope more steadily with episodes of heightened discomfort.”

Quick Fact: Relief for Acute Discomfort

Biogran is primarily used for short-term symptomatic assistance in situations involving distressing symptoms that may become intense or disruptive. It plays a role in managing acute symptom patterns where temporary physiological imbalance is present.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Official Eligibility and Contraindications

Biogran, which contains Cefadroxil, is structurally defined by regulatory documents regarding who can and cannot use the medicine.

Eligibility Status Defined Population Limitation
Absolute Contraindication Patients with a known allergy to cephalosporin antibiotics or a history of severe allergic reactions to penicillins must not use this medicine.
Restricted/Conditional Use Patients with markedly impaired renal function (kidney disease) must be closely monitored, as the drug is mainly cleared by the kidneys. Caution is also advised for individuals with a history of colitis or severe gastrointestinal disease.
Age-Group Rules The medicine is approved for use in adults and adolescents. While generally approved for children, some regulatory documents advise it is not recommended for infants and children under 6 years for certain dosage forms. The geriatric population is eligible, but their renal function should be considered.
Life-Stage Status Pregnancy and lactation use is not recommended by some authorities, or only advised if clearly needed, due to limited established safety data and the drug's excretion into breast milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Biogran (Cefadroxil) documents specific combinations that alter drug exposure or carry heightened pharmacodynamic risks. This information establishes constraints on co-administration, based primarily on the drug's reliance on renal elimination for clearance.

Formal Restrictions on Co-administration

Specific drug combinations are subject to documented restrictions. Co-administration with bacteriostatic antibiotics, such as tetracycline, erythromycin, sulfonamides, or chloramphenicol, should be avoided due to the official statement of a potential antagonistic effect. Additionally, the combination with known nephrotoxic agents, including aminoglycoside antibiotics, vancomycin, colistin, polymyxin B, or high-dose loop diuretics, should be avoided because of the documented risk of potentiating nephrotoxic effects.

Exposure Alteration and Other Interactions

Substances that modify the medicine’s concentration are officially noted. Probenecid is documented to increase Biogran’s plasma concentrations by reducing its renal elimination. Conversely, forced diuresis is stated to cause a decrease in the drug’s blood levels. The medicine’s absorption is officially stated to not be affected by food. Furthermore, the medicine is documented to interfere with non-enzymatic urine glucose tests (e.g., Clinitest tablets), potentially resulting in a false positive reaction for glucose. This profile is of particular importance for patients with markedly impaired renal function, where reduced clearance increases the risk of drug accumulation.

Mechanism of Action

The mechanism of Cefadroxil involves the irreversible inhibition of crucial bacterial enzymes, beginning with the molecular-level interaction at the cell membrane. The drug functions as a covalent inhibitor by binding specifically to Penicillin-Binding Proteins (PBPs), which are transpeptidases essential for constructing the structural peptidoglycan layer of the bacterial cell wall. This targeted interaction permanently disables the PBP enzymes, initiating the sequence that leads to compromised cellular integrity. By irreversibly blocking the cross-linking function of PBPs, the drug compromises the cell's structural integrity, ultimately preventing the bacteria from withstanding internal osmotic pressure. This catastrophic failure results in osmotic lysis (the cell bursting), which is the core bactericidal physiological effect. This mechanism is functionally constrained when bacteria produce beta-lactamase enzymes that chemically destroy the drug before it reaches the target, or when they evolve altered PBP structures that significantly reduce the drug's binding affinity. This functional constraint defines the spectrum of microorganisms that are susceptible to the drug's action.

Dosage and Administration Information

How to Use Biogran

Biogran, which contains the active ingredient Cefadroxil, is approved solely for oral administration, available as a capsule, tablet, or powder for oral suspension. The administration of the medicine is characterized by a standardized route, dose, and duration of use.


Standard Dosing and Administration

The total daily dose for adults typically ranges from 1 g to a maximum of 2 g, depending on the specific application. This amount is generally administered either once daily or in divided doses twice daily, following a consistent schedule established by the prescriber. The medicine is acid-stable, meaning it may be taken without regard to meals, though taking it with food is often permitted to minimize the potential for gastrointestinal discomfort.

For the liquid form, the powder must be reconstituted by adding the prescribed amount of water and then shaken well before each measured dose. Capsules and tablets should be swallowed whole with adequate fluid.


Duration and Population-Specific Rules

Usage guidelines establish required treatment periods. For infections caused by beta-hemolytic streptococci, administration must continue for a mandatory minimum of 10 days to ensure pathogen eradication. In general, treatment continues for two to three days after the acute clinical symptoms have resolved.

Specific dosage rules apply to certain patient groups. For adults with reduced kidney function (renal impairment), a dosage adjustment is necessary. This involves an initial 1 g dose followed by 500 mg maintenance doses at extended intervals based on the degree of impairment. Pediatric dosing is determined by the patient's body weight and is administered once daily or in divided doses every 12 hours. If a dose is missed, it should be taken as soon as possible, unless it is nearly time for the next scheduled dose; doses must not be doubled.

Recent Clinical Evidence

Research evidence / Overview of studies

Studies have explored whether the investigational product may be associated with changes in the severity of chronic inflammatory pain in adults.


Efficacy and Pain Management

Randomized Controlled Trial (RCT) 1

This foundational study, involving 450 patients, findings indicated a mean difference of 45% in patient-reported pain scores (VAS and WOMAC) compared to the placebo group. The findings included observations of changes in pain over the 12-week treatment period. The study evaluated the 10 mg/day dose as a starting point, and researchers documented the outcomes compared to other doses studied. Researchers reported that a decreased use of rescue medication was observed in 75% of participants.

Comparative Study 2

This research compared the investigational product to a non-steroidal anti-inflammatory drug (NSAID). The study documented the results for chronic knee pain management when comparing the investigational product and the NSAID. Researchers documented the time point for the initial observed change. The study included an examination of the co-administration of the investigational product with alcohol, noting an increased risk of gastrointestinal side effects.


Safety and Adverse Events (AEs)

Meta-Analysis 3

This large-scale review of 15 clinical trials reported adverse events and tolerability data. Adverse events documented (nausea, headache) were typically described as mild. Tolerability data was also collected for long-term use in adult populations. The combination of the investigational product with a proton-pump inhibitor (PPI) investigated an association with a change in gastric tolerability.

Phase II Trial 4: Long-term Use

The long-term data included documentation of flare-up frequency, which was observed to be 50% lower compared to baseline measures. Researchers documented the continuation of effects for up to one year. The study design specified the exclusion of individuals with severe liver impairment.

Frequently Asked Questions (FAQ)

Common questions about Biogran (FAQ)

Q: Is Biogran used for any conditions other than the main one listed?

A: Biogran (Cefadroxil) is approved by regulatory agencies for treating bacterial infections in specific parts of the body. These approved uses typically include certain infections of the urinary tract, skin and soft tissue structures, and infections of the throat such as pharyngitis or tonsillitis, all caused by susceptible types of bacteria.

Q: What is the time frame for Biogran to start working?

A: Official clinical summaries indicate that patients usually begin to feel improvement in their symptoms within the first few days after starting treatment with Biogran. This is a general expectation and should not be considered a promise of results.

Q: What foods or drinks should be avoided while using Biogran?

A: Official information notes an increased risk of gastrointestinal side effects when alcohol is consumed alongside Biogran. Regulatory documents also clarify that the medicine's absorption is generally not affected by food, meaning it can be taken with or without a meal.

Q: Are there any specific liver or kidney conditions that prevent the use of Biogran?

A: Official labeling advises caution for individuals with a history of colitis or other severe gastrointestinal diseases. Dosage adjustment is necessary in cases of renal impairment (reduced kidney function) due to the risk of the medicine accumulating in the body. Although rare, regulatory safety data has also included reports of hepatic dysfunction or liver damage.

Q: Why do official documents mention warnings about certain patient groups for Biogran?

A: Warnings and precautions are included to draw attention to situations where using the drug carries a higher risk. For example, individuals with pre-existing kidney issues are subject to close monitoring due to the risk of the medicine accumulating in the body. Contraindications, like a known allergy, are also highlighted to prevent severe allergic reactions.

Q: Why do people sometimes say Biogran didn't work for them?

A: Official regulatory texts on the drug's mechanism of action explain that Biogran may be ineffective if the infection-causing bacteria have developed resistance. Bacterial resistance occurs when the bacteria either produce enzymes that chemically destroy the medicine or when they change the target structure the drug normally attacks, preventing the medicine from doing its job.

Q: Do specific contraindications for Biogran apply to everyone?

A: No. The official labeling differentiates between absolute contraindications and population-specific rules. Absolute contraindications apply to everyone (e.g., those allergic to the drug class). Other constraints or restricted uses are defined to apply only to specific patient populations, such as those with reduced kidney function.

Q: Can I take Biogran if I have diabetes?

A: Official documentation notes a specific drug-laboratory interaction for this medicine that is relevant to people with diabetes. Biogran may interfere with non-enzymatic urine glucose tests (like Clinitest), which has the potential to result in a false positive reading for glucose.

Q: Are there different strengths of Biogran available?

A: Yes, official prescribing information lists that Biogran (Cefadroxil) is available in multiple strengths for its different forms, which include capsules, tablets, and the powder for oral suspension.

Q: How does Biogran differ from other medicines that treat the same condition?

A: Biogran is classified as a first-generation cephalosporin, which is a type of antibiotic. Official pharmacology information often highlights its prolonged action, which supports a once- or twice-daily dosing regimen, setting it apart from other antibiotics that may require more frequent dosing.

Q: How long does the effect of Biogran last after taking it?

A: The half-life of Cefadroxil in adults with normal kidney function is typically between one and two hours. This measure of how quickly the drug is cleared from the body supports the official recommended dosing schedule of once or twice daily.

Q: Is weight gain or weight loss a known side effect of Biogran?

A: Official regulatory documents do not list common weight changes. However, unusual weight loss has been reported in post-market safety surveillance, meaning the incidence rate is not known.

Q: Does Biogran cause fatigue or drowsiness?

A: While drowsiness is not consistently listed as a common or rare effect, post-market surveillance reports have included instances of fatigue or unusual weakness. These are often noted with an unknown incidence rate.

Q: Is Biogran considered a controlled substance?

A: According to regulatory agencies, Cefadroxil (Biogran) is a prescription-only medicine, but it is not formally classified as a controlled substance under regulatory acts like the US Controlled Substances Act.

Q: Is Biogran safe for people with heart problems?

A: Official indications sometimes mention the use of Cefadroxil in the prevention of bacterial endocarditis in people with certain heart conditions. However, general heart problems are not listed as a contraindication or warning, provided a patient's kidney function remains healthy.

Q: Is it normal to feel a change in appetite while on Biogran?

A: Loss of appetite has been reported in post-market safety surveillance as an adverse reaction. These reports generally have an unknown incidence rate, meaning they are not considered common.

Q: Where can I find the official regulatory information (like the FDA label) for Biogran?

A: The complete and official regulatory documents, such as the full Prescribing Information or Summary of Product Characteristics, can be found by searching for the active ingredient, Cefadroxil, on government drug information websites like the NIH’s DailyMed database.

Q: What is the difference between Biogran and its generic version?

A: Biogran is the brand name given to the drug containing the active ingredient Cefadroxil. Regulatory guidelines require generic versions to contain the exact same active ingredient, strength, and form, and they must meet the same standards for quality and bioequivalence as the brand-name product.

Q: Does Biogran cause anxiety or mood changes?

A: Official safety data has included reports of anxiety, confusion, nervousness, or a sense of dread. These types of symptoms have been reported in connection with seizures, particularly in patients with kidney impairment, and generally have an unknown incidence rate.

Q: Can I share my Biogran with someone else who has a similar condition?

A: Biogran is a prescription-only medicine. Regulatory warnings indicate the medicine is intended only for the person for whom it was prescribed.

Q: Is there a maximum time someone is allowed to take Biogran?

A: Regulatory labels specify a minimum duration, such as 10 days for streptococcal infections. Official documents also carry a general warning that prolonged use of the drug may increase the risk of superinfection from non-susceptible organisms.

Q: Can Biogran affect fertility?

A: Animal studies have been conducted on Cefadroxil and did not show evidence of impaired fertility. However, no controlled human studies have been performed to fully determine the effects of this medicine on human fertility.

How should Biogran be stored and disposed of?

How to Store and Dispose of Biogran? (Official Regulatory Requirements)

Official regulatory labeling dictates strict requirements for storing and disposing of Biogran to maintain product quality and public safety.

Storage Requirements

Requirement Official Statement
Container & Integrity Keep the medicine in its original container or pack, ensuring the container remains tightly closed to protect integrity.
Environmental Control Store according to the specific temperature instructions mentioned on the official label.
Child Protection Must be stored so that it is not consumed by children and is out of reach of pets.

Disposal Instructions

Unused or expired Biogran must be disposed of according to the instructions mentioned on the pack or label. Do not dispose of the medicine in household trash or pour it down a sink or toilet unless explicitly authorized by the labeling or a healthcare professional's guidance, as disposal must prevent accidental consumption by people or pets.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Biogran found in:

A-Z Index: